HK1102808A1 - (r/s) rifamycin derivatives, their preparation and pharmaceutical compositions - Google Patents

(r/s) rifamycin derivatives, their preparation and pharmaceutical compositions

Info

Publication number
HK1102808A1
HK1102808A1 HK07110800.2A HK07110800A HK1102808A1 HK 1102808 A1 HK1102808 A1 HK 1102808A1 HK 07110800 A HK07110800 A HK 07110800A HK 1102808 A1 HK1102808 A1 HK 1102808A1
Authority
HK
Hong Kong
Prior art keywords
sub
rifamycin derivatives
preparation
humans
pharmaceutical compositions
Prior art date
Application number
HK07110800.2A
Other languages
English (en)
Inventor
Charles Z Ding
Zhenkun Ma
Jing Li
Susan Harran
Yong He
Keith P Minor
In Ho Kim
Jamie Carol Longgood
Yafei Jin
Keith D Combrink
Original Assignee
Cumbre Ip Ventures L P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cumbre Ip Ventures L P filed Critical Cumbre Ip Ventures L P
Publication of HK1102808A1 publication Critical patent/HK1102808A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
HK07110800.2A 2004-07-22 2007-10-04 (r/s) rifamycin derivatives, their preparation and pharmaceutical compositions HK1102808A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59019004P 2004-07-22 2004-07-22
PCT/US2005/025924 WO2006012443A1 (fr) 2004-07-22 2005-07-21 Derives de la rifamycine (r/s), leur preparation et compositions pharmaceutiques

Publications (1)

Publication Number Publication Date
HK1102808A1 true HK1102808A1 (en) 2007-12-07

Family

ID=35355764

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07110800.2A HK1102808A1 (en) 2004-07-22 2007-10-04 (r/s) rifamycin derivatives, their preparation and pharmaceutical compositions

Country Status (11)

Country Link
US (2) US7226931B2 (fr)
EP (2) EP1768987B1 (fr)
JP (2) JP5153329B2 (fr)
CN (2) CN101031572B (fr)
AT (1) ATE427311T1 (fr)
AU (1) AU2005267054B2 (fr)
CA (2) CA2574301C (fr)
DE (1) DE602005013671D1 (fr)
HK (1) HK1102808A1 (fr)
NZ (1) NZ565002A (fr)
WO (2) WO2006012443A1 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US8425936B2 (en) * 2003-07-21 2013-04-23 Shionogi Inc. Antibiotic product, use and formulation thereof
AU2004258953B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP2006528189A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質産物、その使用法および製剤
CA2535177A1 (fr) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Pastille robuste
AU2004264356B2 (en) * 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
WO2005023184A2 (fr) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Produit antibiotique, son utilisation et sa formulation
CA2538064C (fr) * 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotique, son utilisation et sa formulation
ES2537976T3 (es) 2003-12-12 2015-06-16 Daiichi Sankyo Company, Limited Compuestos intermedios para la producción de derivados de ciclopropilamina ópticamente activos y procedimiento para la producción de los compuestos intermedios
EP1771158A4 (fr) * 2004-07-02 2008-03-12 Advancis Pharmaceutical Corp Comprimé pour distribution par impulsion
GB0505909D0 (en) * 2005-03-23 2005-04-27 Univ Leeds Formulations
AU2006339058B2 (en) 2005-08-11 2012-09-06 Targanta Therapeutics Inc. Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
US7892826B2 (en) 2005-08-15 2011-02-22 Janssen Pharmaceutica N.V. Human cell clones having an endogeneous urotensin II receptor
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
TWI454262B (zh) * 2006-11-02 2014-10-01 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
WO2009064792A1 (fr) * 2007-11-16 2009-05-22 Cumbre Pharmaceuticals Inc. Dérivés de rifamycine substituée par l'acide quinolone-carboxylique
US8067429B2 (en) 2008-02-25 2011-11-29 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
CN101959888A (zh) * 2008-03-05 2011-01-26 塔加西普特公司 二氮杂双环烷烃的烟碱乙酰胆碱受体亚型的选择性酰胺
US8278313B2 (en) * 2008-03-11 2012-10-02 Abbott Laboratories Macrocyclic spiro pyrimidine derivatives
EP2324041A4 (fr) 2008-08-13 2012-06-13 Targanta Therapeutics Corp Rifamycines phosphonées et leurs utilisations pour la prévention et le traitement d'infections des os et des articulations
CN101875658B (zh) * 2009-04-28 2013-01-09 上海药明康德新药开发有限公司 3-羰基-2,8-二氮杂螺[4.5] 癸烷-8-羧酸叔丁酯的制备方法
MX2012004753A (es) 2009-10-23 2012-09-07 Janssen Pharmaceutica Nv Octahidropirrolo[3,4-c]pirrolos disustituidos como moduladores del receptor de orexina.
NZ604035A (en) 2010-06-04 2015-02-27 Albany Molecular Res Inc Glycine transporter-1 inhibitors, methods of making them, and uses thereof
BR112015002945B1 (pt) * 2012-08-13 2021-08-31 Adipharm Ead Formulações farmacêuticas contendo derivados de 3-(4-cinamil-1-piperazinil)-amino de 3- formil-rifamicina sv e 3-formil-rifamicina s e um processo para sua preparação
CN104955457A (zh) * 2012-09-12 2015-09-30 萨利克斯药品公司 给予利福昔明而不产生抗生素耐药性的方法
CN103709177B (zh) * 2013-12-20 2016-02-24 武汉工程大学 利福霉素类沃尼妙林杂合抗生素及其制备方法
CN104628745B (zh) * 2015-03-06 2017-03-08 丹诺医药(苏州）有限公司 一种利福霉素‑喹嗪酮双靶标分子的富马酸盐及其制备方法
CN104710439B (zh) * 2015-03-06 2017-11-07 丹诺医药(苏州）有限公司 一种利福霉素‑喹嗪酮双靶标分子的晶型i及其制备方法
MA43817B1 (fr) 2016-03-10 2022-04-29 Janssen Pharmaceutica Nv Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2
CN105879009A (zh) * 2016-04-18 2016-08-24 丹诺医药(苏州）有限公司 一种用于治疗革兰氏阴性菌感染的抗菌药物组合物
WO2017212423A1 (fr) * 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Composés chimiques
CN106902116B (zh) * 2017-02-28 2021-03-23 丹诺医药(苏州）有限公司 一种利福霉素-喹嗪酮双靶标分子的应用
CN106822125A (zh) * 2017-02-28 2017-06-13 丹诺医药(苏州）有限公司 一种利福霉素‑喹嗪酮双靶标分子的新用途
CN109251258B (zh) * 2017-07-13 2021-06-01 中国石油天然气股份有限公司 宽分布聚丙烯催化组分、组分制备方法及其催化剂
WO2019027860A1 (fr) * 2017-08-01 2019-02-07 Boehringer Ingelheim International Gmbh Composés intermédiaires et procédés
CN108310393A (zh) * 2018-02-12 2018-07-24 丹诺医药(苏州）有限公司 一种利福霉素-喹嗪酮偶联分子的应用
CN109464673A (zh) * 2019-01-08 2019-03-15 丹诺医药(苏州）有限公司 利福霉素-喹嗪酮偶联分子及其盐的应用和制剂
CN109529045B (zh) * 2019-01-08 2021-05-18 丹诺医药(苏州）有限公司 利福霉素-喹嗪酮偶联分子及其药学上可接受的盐的应用
CN109942474B (zh) * 2019-03-04 2020-09-18 华中科技大学 一种邻叠氮-肼类化合物及其制备方法
CN115501230B (zh) * 2022-08-05 2023-11-21 丹诺医药(苏州）有限公司 利福霉素-喹嗪酮偶联分子软膏剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0333176B1 (fr) * 1988-03-18 1995-11-08 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Dérivé de la benzoxazinorifamycine substitué, procédé de préparation et agent antibactérien le contenant
WO1994028002A1 (fr) * 1993-05-24 1994-12-08 Gruppo Lepetit S.P.A. Derives-36 de rifamycines et leur utilisation comme agents anti-microbiens
AU2002360416A1 (en) * 2001-11-21 2003-06-10 Activbiotics, Inc. Targeted therapeutics and uses thereof
US7247634B2 (en) * 2004-01-13 2007-07-24 Cumbre Pharmaceuticals Inc. Rifamycin derivatives effective against drug-resistant microbes
US7238694B2 (en) * 2004-01-13 2007-07-03 Cumbre Pharmaceuticals, Inc. Rifamycin imino derivatives effective against drug-resistant microbes

Also Published As

Publication number Publication date
US7226931B2 (en) 2007-06-05
WO2006012470A1 (fr) 2006-02-02
EP1781670A1 (fr) 2007-05-09
AU2005267054A1 (en) 2006-02-02
CN101065385A (zh) 2007-10-31
DE602005013671D1 (de) 2009-05-14
EP1768987A1 (fr) 2007-04-04
JP5153329B2 (ja) 2013-02-27
EP1768987B1 (fr) 2009-04-01
US20060019985A1 (en) 2006-01-26
US7229996B2 (en) 2007-06-12
WO2006012443A1 (fr) 2006-02-02
CN101031572B (zh) 2010-12-08
CA2574301A1 (fr) 2006-02-02
CA2574307A1 (fr) 2006-02-02
ATE427311T1 (de) 2009-04-15
NZ565002A (en) 2009-08-28
CA2574301C (fr) 2013-09-10
CN101031572A (zh) 2007-09-05
JP5236944B2 (ja) 2013-07-17
JP2008507549A (ja) 2008-03-13
US20060019986A1 (en) 2006-01-26
AU2005267054B2 (en) 2011-06-23
JP2008507548A (ja) 2008-03-13

Similar Documents

Publication Publication Date Title
HK1102808A1 (en) (r/s) rifamycin derivatives, their preparation and pharmaceutical compositions
WO2010032147A3 (fr) Dérivés d'acide hydroxamique utiles comme agents antibactériens
WO2003010135A1 (fr) Nouveaux derives de l'acide phenylpropionique
GB0007405D0 (en) Compounds
KR20050085991A (en) Compounds exhibiting thrombopoietin receptor agonism
WO2008108386A1 (fr) Composition pharmaceutique
TW200628161A (en) Novel betulin derivatives, preparation thereof and use thereof
EP2266623A3 (fr) Promédicaments contenant de nouveaux liens bio-clivables
AU2003222106A1 (en) Thiopene-based tricyclic compounds and pharmaceutical compositions comprising same
MX2009003927A (es) Derivado espirocetal de tioglucosa y uso del mismo como un agente terapeutico para la diabetes.
WO2008151460A3 (fr) Composés de refroidissement
NZ320580A (en) Tricyclic compounds, preparation and pharmaceutical compositions thereof
BRPI0408240A (pt) composto, utilização de um composto e composição farmacêutica
MY141472A (en) Substituted phenyl phenol leukotriene antagonists
WO2007080270A3 (fr) Nouveaux derives de l'oxime de cholest-4-en-3-one, compositions pharmaceutiques les renfermant, et procede de preparation
TW200745153A (en) Trehalose compound and pharmaceutical comprising the compound
MX2007002531A (es) Derivados novedosos de 3,5-seco-4-norcolestan y usos de los mismos.
AU2001282871A1 (en) Antithrombotic agents
WO2007044927A3 (fr) Macrolides tricycliques a pontage 6, 11
TR200200550T2 (tr) Piruvat dehidrojenaz aktivitesini yükselten ikameli n-fenil 2-hidroksi -2- metil -3,3,3- triflüoropropanamid türevleri.
AU2003294031A1 (en) Dust-free pigment compositions obtainable by spray-drying
RS20050837A (en) NEW 3-DECLADINOSYL 9a-N-CARBAMOYL AND 9a-N-THIOCARBAMOYL DERIVATIVES OF 9-DEOX-9-DIHYDRO-9a-AZA-9A- HOMOERYTHROMYCIN A NEW 3- DECLADINOSYL 9A-N-CARBAMOYL AND -A- N-THIOCARBAMOYL DERIVATIVES OF 9- DEOX-9-DIHYDRO-9A-AZA-9A- HOMOERYTHROMYCIN A
RS20050954A (en) Use of bycyclo/2.2.1/heptane derivatives for the preparation of neuroprotective pharmaceutical compositions
NZ515278A (en) Halo derivatives of 9-deoxo-9a-aza-9a- homerythromycin A their salts and preparation process
WO2000064902A3 (fr) Processus de preparation de precurseurs de calanolide